Antimicrobial Management of Sepsis and Septic Shock

被引:30
|
作者
Sharma, Sat [2 ]
Kumar, Anand [1 ,3 ,4 ,5 ]
机构
[1] Univ Manitoba, Hlth Sci Ctr, Infect Dis Sect, Sect Crit Care Med,Dept Internal Med, Winnipeg, MB R3E 0Z3, Canada
[2] Univ Manitoba, Dept Internal Med, Sect Pulm, Winnipeg, MB R3E 0Z3, Canada
[3] Univ Manitoba, Dept Med, Pulm & Crit Care Med Sect, Winnipeg, MB R3E 0Z3, Canada
[4] Univ Manitoba, Dept Med, Infect Dis Sect, Winnipeg, MB R3E 0Z3, Canada
[5] Univ Med & Dent New Jersey, Dept Med, Camden, NJ USA
关键词
Infections; Antibiotics; Sepsis; Septic shock;
D O I
10.1016/j.ccm.2008.06.004
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Every patient who has sepsis and septic shock must be evaluated appropriately at presentation before the initiation of antibiotic therapy. However, in most situations, an abridged initial assessment focusing on critical diagnostic and management planning elements is sufficient. Intravenous antibiotics should be administered as early as possible, and always within the first hour of recognizing severe sepsis and septic shock. Broad-spectrum antibiotics must be selected with one or more agents active against likely bacterial or fungal pathogens and with good penetration into the presumed source. Antimicrobial therapy should be reevaluated daily to optimize efficacy, prevent resistance, avoid toxicity, and minimize costs. Consider combination therapy in septic shock Pseudomonas infections in neutropenic patients. Combination therapy should be continued for no more than 3 to 5 days and de-escalation should occur following availability of susceptibilities. The duration of antibiotic therapy typically is limited to 7 to 10 days. Longer duration is considered if response is slow, if there is inadequate surgical source control, or if immunologic deficiencies are evident. Antimicrobial therapy should be stopped if infection is not considered the etiologic factor for a shock state.
引用
收藏
页码:677 / +
页数:12
相关论文
共 50 条
  • [1] Management of Sepsis and Septic Shock
    Howell, Michael D.
    Davis, Andrew M.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2017, 317 (08): : 847 - +
  • [2] Optimizing Antimicrobial Therapy in Sepsis and Septic Shock
    Kumar, Anand
    [J]. CRITICAL CARE CLINICS, 2009, 25 (04) : 733 - +
  • [4] Optimal antimicrobial therapy and antimicrobial stewardship in sepsis and septic shock
    Seok, Hyeri
    Park, Dae Won
    [J]. JOURNAL OF THE KOREAN MEDICAL ASSOCIATION, 2019, 62 (12): : 638 - 644
  • [5] Current management of sepsis and septic shock
    Vincent, Jean-Louis
    [J]. SIGNA VITAE, 2016, 11 : 14 - 16
  • [6] The Management of Severe Sepsis and Septic Shock
    Morrell, Matthew R.
    Micek, Scott T.
    Kollef, Marin H.
    [J]. INFECTIOUS DISEASE CLINICS OF NORTH AMERICA, 2009, 23 (03) : 485 - +
  • [7] Optimizing Antimicrobial Therapy of Sepsis and Septic Shock Preface
    Kumar, Anand
    [J]. CRITICAL CARE CLINICS, 2011, 27 (01) : XI - XII
  • [8] Sepsis and septic shock: Selection of empiric antimicrobial therapy
    Cunha, Burke A.
    [J]. CRITICAL CARE CLINICS, 2008, 24 (02) : 313 - +
  • [9] Early antimicrobial therapy in severe sepsis and septic shock
    Kumar A.
    [J]. Current Infectious Disease Reports, 2010, 12 (5) : 336 - 344
  • [10] Second Dose Antimicrobial Delays in Sepsis and Septic Shock
    Villarba, J.
    Lewis, K.
    Walus, A.
    Serwylo, O.
    [J]. CANADIAN JOURNAL OF HOSPITAL PHARMACY, 2021, 74 (02): : 174 - 174